Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People between 18 and 75 years old
• People who have been diagnosed with a specific type of kidney cancer (non-clear cell renal cell carcinoma), confirmed by a tissue biopsy — specifically certain subtypes such as papillary RCC (at a certain stage and grade), collecting duct carcinoma, renal medullary carcinoma, FH-RCC, TFE3/TFEB translocation-related kidney cancer, or unclassified kidney cancer meeting certain stage or grade requirements (confirm with trial site for exact subtype eligibility)
• People whose kidney tumour has been fully removed by surgery (partial or full kidney removal), performed no sooner than 3 weeks and no later than 12 weeks before joining the trial
• People who show no signs of remaining tumour or spread to other parts of the body after surgery — or, if there was a single isolated spread to soft tissue, people whose metastasis was also fully removed with no remaining disease
• People who have not yet received any systemic (whole-body) treatment for their kidney cancer
• People who are generally well enough to carry out normal daily activities with little to no limitation (as assessed by a standard medical scale)
• People whose blood counts, kidney, liver, and heart function all fall within acceptable ranges as measured by blood tests, and whose heart pumping function is at least 50%
• People who are willing and able to use highly effective contraception during the trial and for 3 months after the last dose
• People who are able and willing to attend all required study visits and follow-up appointments
• People who have signed a form confirming they understand and agree to take part in the trial

Who may not be able to join:

• People whose kidney cancer is of the clear cell, chromophobe, or eosinophilic subtype
• People who have previously received immunotherapy treatments targeting the immune system (such as anti-PD-1, PD-L1, or CTLA-4 drugs, or certain cytokine therapies)
• People who have previously received treatments targeting VEGF, VEGFR, or mTOR (specific cancer-targeting drug pathways)
• People who have taken part in another clinical drug trial within the past 4 weeks, or who have had major surgery within 4 weeks before joining
• People who have taken certain traditional Chinese medicines, steroid medications (above a low threshold), or immune-suppressing drugs within the 2 weeks before joining — though people on low-dose steroids with no active autoimmune disease may still be considered (confirm with trial site)
• People who still have unresolved side effects from a previous cancer treatment — though people with permanent but stable side effects not expected to worsen may still be considered (confirm with trial site)
• People who have had another cancer in the past 5 years that is active or requires treatment — with some exceptions for certain fully treated skin cancers or early-stage cancers in situ (confirm with trial site)
• People who have a history of cancer spreading to the brain, or whose recent scans (within 30 days) show brain involvement
• People with high blood pressure that cannot be adequately controlled with medication (remaining at or above 150/100 mmHg)
• People who have experienced a heart attack, unstable chest pain, heart surgery or stenting, heart bypass surgery, severe heart failure, stroke, or a mini-stroke within the past 6 months
• People with a significantly prolonged heart electrical interval (QTc of 500 milliseconds or more) on a heart tracing
• People with a history of serious or active bleeding within the past 30 days, or coughing up blood within the past 6 weeks
• People who have had a blood clot in a deep vein or in the lungs within the past 6 months
• People with significant digestive system problems, including conditions affecting how oral medications are absorbed, active stomach ulcers treated within the past 6 months, recent gastrointestinal bleeding without confirmed healing, or conditions that may increase the risk of bowel perforation or inflammation
• People who have had an organ transplant that requires long-term steroid treatment
• People who have current or past non-infectious lung inflammation requiring steroid treatment
• People with an active infection needing treatment, a known HIV diagnosis, or active hepatitis B or C infection
• People who have received a live vaccine within 30 days before joining
• People with a known history of serious drug allergies
• People with a known history of significant psychiatric illness or substance misuse
• People with wounds that have not yet healed
• People who have taken, or are expected to take, certain medications that strongly interact with the CYP3A4/5 enzyme pathway within 7 days before joining (confirm specific medications with trial site)
• People whom the trial doctors consider unsuitable for any medical or safety reason

Important: Always verify eligibility with the trial site directly before applying.